Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Homozygous Familial Hypercholesterolemia (HoFH)~* Stable lipid-lowering therapy for 12 weeks~* Stable weight for 6 weeks~* Stable low fat diet for 8 weeks~Exclusion Criteria:~* Significant health problems in the recent past including heart attack, stroke, blood disorders, cancer, or digestive problems

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mipomersen (Type: EXPERIMENTAL): Participants received mipomersen 200 mg as a subcutaneous injection once a week for 26 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo as a subcutaneous injection once a week for 26 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).